You just read:

Eravacycline's Improvements in Efficacy and Delivery Over Competitors will Drive Uptake for the Treatment of Gram-Negative Infections due to Multidrug-Resistant Enterobacteriaceae

News provided by

Decision Resources Group

Apr 23, 2014, 11:30 ET